Innovative Cell Therapy Zelluna specializes in allogeneic TCR-guided NK cell immunotherapies targeting solid cancers, presenting a strong opportunity for partners and clients in the oncology biotech sector seeking cutting-edge treatment solutions.

Broad Accessibility Focus With proprietary scalable manufacturing processes aimed at broad patient accessibility, Zelluna offers potential for collaborations or supply agreements that can expand treatment reach and commercialization efforts.

Strategic Partnerships Recent collaborations with Catalent for process development and manufacturing, along with a merger with Ultimovacs, highlight Zelluna's active engagement in strategic alliances, providing avenues for joint development, licensing, or distribution deals.

Funding & Growth Having secured $4.6M in funding and generating revenue between 1 to 10 million dollars, Zelluna demonstrates growth potential and opportunity for investors or partners interested in early-stage biotech innovation.

Leadership & Market Presence Recent hires including a Chief Business Officer to strengthen US presence signal Zelluna's focus on expanding market access and forging new commercial relationships, ideal for sales partners looking to capitalize on international growth.